Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Mechanism, Trial Evidence & UK Status An evidence-based overview of retatrutide the first-in-class triple hormone receptor agonist covering how it is studied to work, the published clinical-trial data, and its research-use-only status in the UK
188 TrusolinoL.ComoglioP
The research record is based on animal models and mechanistic reasoning
Available Formats Select strength and pack size Review the listed strengths first, then choose the pack format that fits the current research order
US$ 27.67
US$ 23.03
US$ 28.14
US$ 29.94
